Medivir (MVIRB) has submitted an application for marketing authorization to the European regulatory authorities to patent Lipsovir—a topical product that prevents and treats cold sores.

Lipsovir is clinically proven to provide indivudals more resistance to the common cold sore. According to the product testing results, cold sores can be prevented with early treatment initiation, something that Lipsovir offers consumers.

That’s why Medivir is more than happy to forward the application. Börje Darpö, Head of Medivir's clinical development department comments, “"We have achieved a substantial and important milestone for Lipsovir® in filing registration applications in both USA and Europe.”